KUPPER et al., Serial No. 09/529,795

CLEAN VERSION OF AMENDMENTS IN THE SPECIFICATION

Please amend line 1 of page 1 to read as follows:

TITLE OF THE INVENTION

"The use of TNF antagonists as drugs for treating septic disorders"

Please amend the paragraph found on lines 5-6 of page 1 to read as follows:

"BACKGROUND OF THE INVENTION

1. FIELD OF THE INVENTION

The present invention relates to the use of TNF antagonists for treating septic disorders."

Please amend the paragraph found on lines 8-10 of page 1 to read as follows:

"2. DESCRIPTION OF THE RELATED ART

It is known that the term tumor necrosis factor (TNF) embraces two cytotoxic factors (TNF- α and TNF- β) which are mostly produced by activated lymphocytes and monocytes."

Please amend the paragraph found on lines 36-38 of page 2 to read as follows:

"BRIEF SUMMARY OF THE INVENTION

It is an object of the present invention to identify, reliably and rapidly, those patients suffering from sepsis who can be successfully treated with TNF antagonists."

KUPPER et al., Serial No. 09/529,795

Please amend the paragraph found on lines 4-7 of page 3 to read as follows:

"BRIEF DESCRIPTION OF THE DRAWINGS

The figure shows that a decrease in mortality can be achieved by the treatment in the group with increasing IL-6 level.

DETAILED DESCRIPTION OF THE INVENTION

at

The treatment is preferably carried out on patients whose serum level of interleukin-6 in the measurement period is at least 500 pg/ml. However, it may also be distinctly higher than this level and be up to the order of a few mg/ml."